In a significant regulatory shift impacting the supplement and chemical research industries, the U.S. Drug Enforcement Administration (DEA) has formally moved to exert tighter control over synthetic derivatives of Mitragyna speciosa, commonly known as kratom. As of August 25, 2026, the agency has enacted a temporary scheduling order placing three potent synthetic alkaloids—mitragynine pseudoindoxyl, MGM-15, and MGM-16—into Schedule I of the Controlled Substances Act (CSA).
This action, which follows a period of public notice and comment, marks a pivotal moment in the government’s approach to the rapidly evolving market of "designer" kratom products. While the DEA emphasizes that this order does not target traditional, naturally occurring botanical kratom, the inclusion of synthetic variants underscores growing federal concerns regarding opioid-like potency and public safety.
A Chronology of Federal Action
The path to this scheduling order began in earnest on July 1, 2026, when the DEA published two Federal Register notices outlining its intent to classify specific kratom-related substances as Schedule I. The first notice addressed three synthetic alkaloids: mitragynine pseudoindoxyl, MGM-15, and MGM-16. A concurrent notice targeted 7-hydroxymitragynine (7-OH), specifically focusing on products that exceed certain concentration thresholds.
Following the mandatory 30-day public comment period, the Office of the Assistant Secretary for Health (OASH) reviewed submissions and forwarded them to the Attorney General. With the authority delegated to the DEA Administrator, the agency proceeded to finalize the temporary scheduling order on August 25, 2026. This emergency action, taken under the DEA’s authority to mitigate "imminent hazards to public safety," remains in effect for two years, with the potential for a one-year extension if further legislative or administrative actions are not taken.
Understanding the Targeted Substances
The substances identified by the DEA represent a departure from the traditional consumption of raw or dried kratom leaf. According to federal researchers, there has been a notable shift in the marketplace toward standardized, semi-synthetic, and highly concentrated alkaloids.
- Mitragynine pseudoindoxyl: A chemical rearrangement product of 7-hydroxymitragynine.
- MGM-15: A synthetic derivative of 7-hydroxymitragynine.
- MGM-16: The 9-fluoro derivative of mitragynine pseudoindoxyl.
While some of these substances have not yet achieved widespread commercial saturation, the DEA has characterized them as posing severe risks. Preclinical data suggests that these synthetic compounds exhibit a high affinity for mu-opioid receptors. In animal models, these substances have demonstrated opioid-like effects, including physical dependence, respiratory depression, and potencies significantly higher than those found in natural kratom leaf. For instance, reports indicate that mitragynine pseudoindoxyl is roughly 100 times more potent than mitragynine, while MGM-15 and MGM-16 have shown potency levels between 50 and 240 times that of morphine.
The Legal and Regulatory Framework
Under the Controlled Substances Act, Schedule I is reserved for drugs with a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The DEA justifies its decision by citing the three primary factors set forth in 21 U.S.C. § 811(c):
- History and Current Pattern of Abuse: The DEA noted the rise of "deceptive marketing," where synthetic products were sold under the guise of being traditional kratom to help with stress or "mental clarity," while actually delivering potent, addictive, opioid-like effects.
- Scope, Duration, and Significance of Abuse: With an estimated 2 million users of various kratom products by 2022, the DEA expressed concern over the low barrier to entry for these synthetics, often packaged in appealing, "fruity" or chewable formats that lack age-gating at the retail level.
- Risk to Public Health: The agency concluded that the risk of toxicity and physical dependence, coupled with the lack of regulation on concentration levels, creates an immediate threat to public safety.
Implications for Researchers and Retailers
The immediate consequence of the August 25 order is a cessation of commercial sales for products containing these three substances. Retailers are now prohibited from selling these compounds, and individuals who possess them without a Schedule I license are in violation of federal law.
For the scientific community, the ruling is equally restrictive. Researchers wishing to continue studying these alkaloids must now obtain specialized Schedule I licenses. Existing research materials must be surrendered or secured in accordance with strict DEA protocols. The agency maintains that these steps are necessary because the U.S. Department of Health and Human Services (HHS) and the FDA have confirmed these substances lack any accepted medical utility.
The 7-OH Threshold Debate
While the three aforementioned substances are now firmly in Schedule I, the status of 7-hydroxymitragynine (7-OH) remains a subject of ongoing administrative focus. The DEA has proposed a threshold-based approach for 7-OH, suggesting that botanical kratom products containing more than 0.050% of 7-OH on a dry weight basis could be subject to scheduling.
This proposal has triggered a secondary public comment period, extended by the OASH until September 10, 2026. Legal experts have highlighted a significant ambiguity regarding the terminology used in the proposal. The DEA uses the word "article" to define the scope of the scheduling, a term that is not clearly defined within the CSA. In the context of the Federal Food, Drug, and Cosmetic Act (FD&C Act), "article" has historically been debated in court—specifically whether it refers to a "finished product" or an individual unit dosage. This lack of clarity creates a complex landscape for manufacturers who must determine if their products fall under the threshold based on the total package or individual units.
Official Responses and Industry Outlook
The federal government maintains that this regulatory tightening is a targeted response to the "proliferation" of dangerous synthetic knock-offs, rather than an attempt to ban the entire botanical kratom industry. However, industry stakeholders remain concerned about the broader precedent being set.
Brian Malkin, Co-Chair of the Spencer Fane Cannabis and FDA Pharmaceutical and Biologics Market Teams, notes that the regulatory environment is in significant flux. "Manufacturers, retailers, and researchers for products containing these kratom-related substances should continue to monitor the DEA’s scheduling orders," Malkin advises. "The deadlines for compliance have been moving rapidly, and companies must develop robust action plans to ensure they remain on the right side of federal law."
The OASH has clarified that it is not currently soliciting comments on the general safety of traditional kratom or broader policy questions regarding the plant’s utility. Instead, the focus is strictly on the technical thresholds for temporary scheduling.
Conclusion: Navigating an Uncertain Future
As the dust settles on the August 25 ruling, the divide between natural botanical products and synthetic derivatives has become the central fault line in the kratom regulatory debate. While the DEA’s current action provides a clear "bright line" regarding the status of mitragynine pseudoindoxyl, MGM-15, and MGM-16, the ongoing deliberation over 7-OH concentrations suggests that the regulatory landscape will continue to shift.
For stakeholders, the directive is clear: the era of unregulated, high-potency synthetic kratom derivatives is over. Compliance now requires rigorous analytical testing to ensure product concentrations remain within federal bounds, and a thorough understanding of the distinction between botanical extracts and synthesized chemical compounds. As federal agencies refine their oversight, the industry must prepare for sustained scrutiny, requiring a proactive, legal-first approach to research and distribution.
About the Author
